Tisa: A Language Design and Modular Verification Technique for Temporal Policies in Web Services

Web services are distributed software components, that are decoupled from each other using interfaces with specified functional behaviors. However, such behavioral specifications are insufficient to demonstrate compliance with certain temporal non-functional policies. An example is demonstrating that a patient’s health-related query sent to a health care service is answered only by a doctor (and not by a secretary). Demonstrating compliance with such policies is important for satisfying governmental privacy regulations. It is often necessary to expose the internals of the web service implementation for demonstrating such compliance, which may compromise modularity. In this work, we provide a language design that enables such demonstrations, while hiding majority of the service’s source code. The key idea is to use greybox specifications to allow service providers to selectively hide and expose parts of their implementation. The overall problem of showing compliance is then reduced to two subproblems: whether the desired properties are satisfied by the service’s greybox specification, and whether this greybox specification is satisfied by the service’s implementation. We specify policies using LTL and solve the first problem by model checking. We solve the second problem by refinement techniques

Quantum singularities in a model of f(R) Gravity

The formation of a naked singularity in a model of f(R) gravity having as source a linear electromagnetic field is considered in view of quantum mechanics. Quantum test fields obeying the Klein-Gordon, Dirac and Maxwell equations are used to probe the classical timelike naked singularity developed at r=0. We prove that the spatial derivative operator of the fields fails to be essentially self-adjoint. As a result, the classical timelike naked singularity remains quantum mechanically singular when it is probed with quantum fields having different spin structures.Comment: 12 pages, final version. Accepted for publication in EPJ

How the design of JML accommodates both runtime assertion checking and formal verification

Specifications that are used in detailed design and in the documentation of existing code are primarily written and read by programmers

Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis

Background: Checkpoint inhibitors (CPI) in combination with cell-based vaccines may produce synergistic antitumor immunity. The primary analysis of the randomized and blinded phase IIb trial in resected stage III/IV melanoma demonstrated TLPLDC is safe and improved 24-month disease-free survival (DFS) in the per treatment (PT) analysis. Here, we examine efficacy within pre-specified and exploratory subgroups. Methods: Stage III/IV patients rendered disease-free by surgery were randomized 2:1 to TLPLDC vaccine versus placebo. The pre-specified PT analysis included only patients completing the primary vaccine/placebo series at 6 months. Kaplan–Meier analysis was used to compare 24-month DFS among subgroups. Results: There were no clinicopathologic differences between subgroups except stage IV patients were more likely to receive CPI. In stage IV patients, 24-month DFS was 43% for vaccine versus 0% for placebo (p = 0.098) in the ITT analysis and 73% versus 0% (p = 0.002) in the PT analysis. There was no significant difference in 24-month DFS when stratified by use of immunotherapy or CPI. For patients with resected recurrent disease, 24-month DFS was 88.9% versus 33.3% (p = 0.013) in the PT analysis. All benefit from vaccination was in the PT analysis; no benefit was found in patients receiving up to three doses. Conclusion: The TLPLDC vaccine improved DFS in patients completing the primary vaccine series, particularly in the resected stage IV patients. The efficacy of the TLPLDC vaccine will be confirmed in a phase III study evaluating adjuvant TLPLDC + CPI versus Placebo + CPI in resected stage IV melanoma patients. © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.Open access journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]